Core Viewpoint - Jasper Therapeutics, Inc. is advancing its clinical-stage antibody therapy briquilimab, targeting mast cell-driven diseases, with a significant presentation scheduled at the 2025 AAD Annual Meeting [1][2] Company Overview - Jasper Therapeutics is focused on developing briquilimab as a treatment for chronic mast cell diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [2] - Briquilimab is a targeted aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to the c-Kit receptor, leading to mast cell depletion and reduced inflammation [2] Clinical Study Details - The upcoming presentation will showcase data from the Phase 1b/2a BEACON study, highlighting briquilimab's rapid and clinically meaningful reduction in disease activity in adults with CSU [2] - The presentation is scheduled for March 8, 2025, at 1 p.m. PST during the Late Breaking Research session at the AAD Annual Meeting [2]

Financial Performance - Jasper Therapeutics reported a net loss of $24.3 million for Q4 2024, compared to a net loss of $16.6 million in Q4 2023, resulting in a basic and diluted net loss per share of $1.62 and $4.89 for the year, respectively[9]. - Research and development expenses for Q4 2024 were $19.8 million, an increase from $13.8 million in Q4 2023, while total operating expenses for the year were $76.2 million, up from $68.9 million in 2023[9]. - Jasper's total operating expenses for the year included $55.8 million in research and development and $20.4 million in general and administrative expenses[9]. - Total current assets decreased from $88,938 million in December 2023 to $75,811 million in December 2024, a decline of approximately 14.8%[11]. - Cash and cash equivalents dropped from $86,887 million in December 2023 to $71,637 million in December 2024, representing a decrease of about 17.5%[11]. - Total liabilities increased from $16,452 million in December 2023 to $18,225 million in December 2024, an increase of approximately 10.7%[11]. - Current liabilities rose from $12,374 million in December 2023 to $15,237 million in December 2024, marking an increase of about 23.1%[11]. - Accumulated deficit widened from $(169,600) million in December 2023 to $(240,869) million in December 2024, reflecting a deterioration of approximately 42.0%[11]. - Total stockholders' equity decreased from $78,440 million in December 2023 to $61,674 million in December 2024, a decline of about 21.3%[11]. - Additional paid-in capital increased from $248,039 million in December 2023 to $302,541 million in December 2024, an increase of approximately 21.9%[11]. - Non-current portion of operating lease liabilities decreased from $1,814 million in December 2023 to $724 million in December 2024, a reduction of about 60.0%[11]. - Property and equipment, net declined from $2,727 million in December 2023 to $1,875 million in December 2024, a decrease of approximately 31.3%[11]. - Prepaid expenses and other current assets increased from $2,051 million in December 2023 to $4,174 million in December 2024, an increase of about 103.5%[11]. Clinical Studies and Developments - The BEACON Phase 1b/2a study showed a more than 25-point improvement in urticaria activity score (UAS7) for multiple dosing regimens of briquilimab at doses ≥120mg[3]. - In the SPOTLIGHT Phase 1b/2a study, 93% of participants achieved a clinical response within six weeks, with 83% of those in the 120mg cohort experiencing a complete response[5]. - Jasper has regulatory clearance to evaluate 240mg Q8W and a 240mg loading dose followed by 180mg Q8W in the BEACON study, with data expected mid-2025 from four cohorts[3]. - The company plans to advance briquilimab into a pivotal Phase 2b study in CSU, expected to commence in the second half of 2025[2]. - Jasper commenced an open-label extension study for chronic urticarias, with initial data from approximately 30 patients expected around mid-2025[5]. - The ETESIAN Phase 1b/2a clinical challenge study for asthma has begun, aiming to enroll approximately 30 patients across seven sites in Canada[5].

Core Viewpoint - Jasper Therapeutics is advancing its clinical-stage antibody therapy, briquilimab, targeting mast cell-driven diseases, with promising data from recent studies indicating its potential efficacy and safety profile [2][3]. Clinical Development - The BEACON study for chronic spontaneous urticaria (CSU) and the SPOTLIGHT study for chronic inducible urticaria (CIndU) have shown positive preliminary results, supporting the advancement of briquilimab into a pivotal Phase 2b study [2][3]. - In the BEACON study, multiple dosing regimens of briquilimab (≥120mg) demonstrated over 25 points improvement in weekly urticaria activity score (UAS7), with clinical responses observed as early as one week post-administration [3]. - The SPOTLIGHT study reported that 93% of participants achieved a clinical response within six weeks, with 83% in the 120mg cohort experiencing a complete response [3]. Financial Performance - For the fiscal year ended December 31, 2024, Jasper reported a net loss of $71.3 million, with a basic and diluted net loss per share of $4.89 [7][10]. - Research and development expenses for the year were $55.8 million, while general and administrative expenses totaled $20.4 million [7][10]. - As of December 31, 2024, the company had cash and cash equivalents of $71.6 million [7][12]. Future Expectations - Jasper plans to commence a Phase 2b operationally adaptive study for briquilimab in CSU in the second half of 2025, with additional data expected from ongoing studies [3][7]. - The company is also conducting an open-label extension study for chronic urticarias and has initiated the ETESIAN Phase 1b/2a clinical challenge study for asthma, with initial data expected in the second half of 2025 [7][8].

Core Insights - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, an antibody therapy targeting c-Kit (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][3] Conference Participation - Jasper will participate in the TD Cowen 45th Annual Healthcare Conference from March 3-5, 2025, with a presentation scheduled for March 3 at 1:20 p.m. EST [2] - The company will also present at the Barclays 27th Annual Global Healthcare Conference from March 11-13, 2025 [2] - Additionally, Jasper will take part in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, at 12:30 p.m. EST [2] Product Development - Briquilimab is a targeted aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to the c-Kit receptor, leading to mast cell depletion via apoptosis, which addresses the inflammatory response in mast cell driven diseases [3] - The therapy has shown efficacy and safety in clinical studies involving patients and healthy volunteers, with positive outcomes reported in CSU and CIndU [3]

Core Insights - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][4] Presentation Details - Jasper will present five posters and one oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting from February 28 to March 3, 2025, in San Diego, CA [1] - The oral presentation titled "Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)" is scheduled for March 1, 2025, at 2:55 p.m. PST [2] - Additional poster presentations will cover various aspects of briquilimab's effects, including its ability to induce mast cell depletion and inhibit SCF/c-Kit signaling [2] Mechanism of Action - Briquilimab is an aglycosylated monoclonal antibody that blocks stem cell factor from binding to c-Kit, disrupting survival signals and leading to mast cell depletion through apoptosis [3][4] - This mechanism addresses the underlying inflammatory response in mast cell driven diseases, potentially offering therapeutic benefits for patients with CSU, CIndU, and asthma [4]

Company Overview - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][3] - Briquilimab is an aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to c-Kit, leading to the depletion of mast cells and addressing the inflammatory response in these diseases [3] Clinical Development - Jasper is currently conducting clinical studies of briquilimab for patients with CSU, CIndU, and asthma, demonstrating efficacy and safety in previous trials [3] - Positive clinical outcomes have been reported for briquilimab in treating CSU and CIndU [3] Upcoming Events - Jasper's management will present at the Oppenheimer Healthcare Life Sciences Conference on February 11, 2025, at 3:20 p.m. EST, in a fireside chat format [2] - A live webcast of the presentation will be available on Jasper's Investor Relations website, with an archived replay accessible for 30 days post-event [2]

Core Insights - Jasper Therapeutics reported positive preliminary data from the BEACON Phase 1b/2a study of briquilimab, showing rapid and durable clinical responses in patients with chronic spontaneous urticaria (CSU) [2][3][17] - The study demonstrated significant reductions in Urticaria Activity Score over 7 days (UAS7), with a mean change of -26.6 in the 240mg single-dose cohort at 8 weeks [2][6][8] - The company plans to initiate a registrational program for briquilimab in CSU, with a Phase 2b study expected to start in the second half of 2025 [16][17] Study Results - In the BEACON study, 100% of patients in the 240mg single-dose cohort achieved complete responses (UAS7 = 0) at 8 weeks, with 66% maintaining well-controlled disease at 12 weeks [2][6][8] - Multiple dosing regimens at or above 120mg showed UAS7 changes of more than -25 points, indicating substantial clinical activity [2][6][10] - Serum tryptase levels were significantly reduced, with 100% of participants in the 240mg cohort achieving levels below the lower limit of quantification by week 1 [13][14] Safety Profile - Briquilimab was well tolerated, with no dose-limiting toxicities reported and only low-grade adverse events observed [14] - Predictable decreases in neutrophil counts were noted, which generally recovered before subsequent doses [14] Future Plans - Jasper is conducting an open-label extension study for patients transitioning from the BEACON study to a 180mg Q8W dose [15] - The company has submitted for regulatory review of additional BEACON cohorts, including 240mg Q8W and 180mg Q8W following a 240mg induction dose [15][16] - Data from additional cohorts are expected to be presented by mid-2025, further informing the registrational program [16]

Core Viewpoint - Jasper Therapeutics, Inc. is hosting a virtual webinar on January 8, 2025, to present preliminary data from the BEACON study of briquilimab, a novel antibody therapy targeting c-Kit for mast cell driven diseases [1][2] Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab as a treatment for chronic mast cell diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [2] - Briquilimab is an aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to the c-Kit receptor, leading to mast cell depletion and reduction of inflammatory responses [2] - The company has reported positive clinical outcomes for briquilimab in CIndU and is currently conducting clinical studies for its efficacy in CSU, CIndU, and asthma [2] Upcoming Event - The webinar will feature management presentations and remarks from Dr. Thomas B. Casale, a leading investigator in the BEACON study [1]

Core Insights - Jasper Therapeutics has initiated dosing in its Phase 1b/2a clinical study, ETESIAN, to evaluate briquilimab for allergic asthma, marking a significant milestone in its clinical programs targeting mast cell-driven diseases [1][2] Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for chronic mast and stem cell diseases, including chronic urticaria and asthma [5] - Briquilimab has shown efficacy and safety in over 160 participants and healthy volunteers, with clinical outcomes in chronic inducible urticaria (CIndU) and as a conditioning agent in various severe conditions [4][5] Clinical Study Details - The ETESIAN study aims to enroll approximately 30 patients across 7 sites in Canada, utilizing a single 180mg subcutaneous dose of briquilimab [2] - Key objectives include demonstrating proof-of-concept in asthma, assessing early and late asthmatic responses, airway hyperresponsiveness, mast cell depletion, and safety [2][4] Mechanism of Action - Briquilimab functions as a targeted aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to c-Kit, leading to mast cell depletion and potentially alleviating inflammatory responses in mast cell-driven diseases [4][5] - The mechanism of mast cell depletion via c-Kit inhibition is considered novel and may address safety issues seen with other c-Kit inhibitors [3]

Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmac ...